It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Idiopathic pulmonary fibrosis (IPF) is characterized by aberrant lung remodeling and the excessive accumulation of extracellular matrix (ECM) proteins. In a previous study, we found that the levels of ornithine aminotransferase (OAT), a principal enzyme in the proline metabolism pathway, were increased in the lungs of patients with IPF. However, the precise role played by OAT in the pathogenesis of IPF is not yet clear. The mechanism by which OAT affects fibrogenesis was assessed in vitro using OAT-overexpressing and OAT-knockdown lung fibroblasts. The therapeutic effects of OAT inhibition were assessed in the lungs of bleomycin-treated mice. OAT expression was increased in fibrotic areas, principally in interstitial fibroblasts, of lungs affected by IPF. OAT levels in the bronchoalveolar lavage fluid of IPF patients were inversely correlated with lung function. The survival rate was significantly lower in the group with an OAT level >75.659 ng/mL than in the group with an OAT level ≤75.659 ng/mL (HR, 29.53; p = 0.0008). OAT overexpression and knockdown increased and decreased ECM component production by lung fibroblasts, respectively. OAT knockdown also inhibited transforming growth factor-β1 (TGF)-β1 activity and TGF-β1 pathway signaling. OAT overexpression increased the generation of mitochondrial reactive oxygen species (ROS) by activating proline dehydrogenase. The OAT inhibitor L-canaline significantly attenuated bleomycin-induced lung injury and fibrosis. In conclusion, increased OAT levels in lungs affected by IPF contribute to the progression of fibrosis by promoting excessive mitochondrial ROS production, which in turn activates TGF-β1 signaling. OAT may be a useful target for treating patients with fibrotic lung diseases, including IPF.
Targeting OAT: a potential therapeutic pathway for fibrotic lung disease
Idiopathic pulmonary fibrosis (IPF, a chronic lung disease marked by excessive buildup of extracellular matrix or ECM, substances that provide structural support to cells, in the lungs) is still not fully understood, especially the role of ornithine aminotransferase (OAT, an enzyme that helps convert ornithine into proline). This study found that OAT was more present in the lungs of IPF patients, especially in areas with severe fibrotic (excessive tissue) remodeling. Increased OAT led to more fibroblast (cells that produce collagen and other fibers) growth, while less OAT reduced it. The study concluded that high OAT levels in IPF lungs contribute to fibrosis progression by enhancing TGF-β1 (a protein that controls cell growth and division) activity and increasing mitochondrial ROS generation. The findings suggest that stopping OAT may reduce fibrosis, offering a potential new treatment for IPF. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Soonchunhyang University Bucheon Hospital, Division of Allergy and Respiratory Medicine, Department of Internal Medicine, Bucheon, South Korea (GRID:grid.412674.2) (ISNI:0000 0004 1773 6524)
2 Soonchunhyang University Bucheon Hospital, Department of Pathology, Bucheon, South Korea (GRID:grid.412674.2) (ISNI:0000 0004 1773 6524)
3 Environmental Health Center Kangwon National University, Gangwondaehakgil, Department of Internal Medicine, Chuncheon-si, South Korea (GRID:grid.412010.6) (ISNI:0000 0001 0707 9039)
4 Gachon University, Gil Medical Center, Department of Allergy, Pulmonary and Critical Care Medicine, Incheon, South Korea (GRID:grid.411653.4) (ISNI:0000 0004 0647 2885)